-
1
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
-
Targan S.R., Hanauer S.B., van Deventer S.J.H., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
van Deventer, S.J.H.3
-
2
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial
-
Hanauer S.B., Feagan B.G., Lichtensein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtensein, G.R.3
-
3
-
-
0033529049
-
Infliximab for the treatment of fistulas in patients with Crohn's disease
-
Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
-
(1999)
N Engl J Med
, vol.340
, pp. 1398-1405
-
-
Present, D.H.1
Rutgeerts, P.2
Targan, S.3
-
4
-
-
10744221312
-
Infliximab maintenance therapy for fistulizing Crohn's disease
-
Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
-
(2004)
N Engl J Med
, vol.350
, pp. 876-885
-
-
Sands, B.E.1
Anderson, F.H.2
Bernstein, C.N.3
-
5
-
-
10744224387
-
Comparison of scheduled and episodic treatment strategies in Crohn's disease
-
Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies in Crohn's disease. Gastroenterology 126 (2004) 402-413
-
(2004)
Gastroenterology
, vol.126
, pp. 402-413
-
-
Rutgeerts, P.1
Feagan, B.G.2
Lichtenstein, G.R.3
-
6
-
-
3042579454
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
-
Hanauer S.B., Wagner C.L., Bala A., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 542-553
-
-
Hanauer, S.B.1
Wagner, C.L.2
Bala, A.3
-
7
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
-
Baert F., Norman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Eng J Med 348 (2003) 601-608
-
(2003)
N Eng J Med
, vol.348
, pp. 601-608
-
-
Baert, F.1
Norman, M.2
Vermeire, S.3
-
8
-
-
0037379792
-
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized trial
-
Farrell R.J., Alsahli M., Jeen Y.-T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized trial. Gastroenterology 124 (2003) 917-924
-
(2003)
Gastroenterology
, vol.124
, pp. 917-924
-
-
Farrell, R.J.1
Alsahli, M.2
Jeen, Y.-T.3
-
9
-
-
0036269445
-
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
-
St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
-
(2002)
Arthritis Rheum
, vol.46
, pp. 1451-1459
-
-
St Clair, E.W.1
Wagner, C.L.2
Fasanmade, A.A.3
-
10
-
-
0019319257
-
A simplified index of Crohn's disease activity
-
Harvey R.F., and Bradshaw J.M. A simplified index of Crohn's disease activity. Lancet 1 (1980) 514
-
(1980)
Lancet
, vol.1
, pp. 514
-
-
Harvey, R.F.1
Bradshaw, J.M.2
-
11
-
-
4744375545
-
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
-
Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004) 505-512
-
(2004)
Gastrointest Endosc
, vol.60
, pp. 505-512
-
-
Daperno, M.1
D'Haens, G.2
Van Assche, G.3
-
12
-
-
71249119542
-
Relationship between infliximab pharmacokinetics and improvement in Crohn's disease
-
(abstract)
-
Fasanmade A., Olson A., Bao W., et al. Relationship between infliximab pharmacokinetics and improvement in Crohn's disease. (abstract). Gastroenterlogy 122 (2002) W1364
-
(2002)
Gastroenterlogy
, vol.122
-
-
Fasanmade, A.1
Olson, A.2
Bao, W.3
-
13
-
-
26644433889
-
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
-
Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
-
(2005)
Lancet
, vol.366
, pp. 1367-1374
-
-
Reich, K.1
Nestle, F.O.2
Papp, K.3
-
14
-
-
27944453865
-
Endoscopic and histological evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease
-
Geboes K., Rutgeerts P., Opdenakker G., et al. Endoscopic and histological evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 21 (2005) 1741-1754
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 1741-1754
-
-
Geboes, K.1
Rutgeerts, P.2
Opdenakker, G.3
-
15
-
-
24644474678
-
Correlation of C-reactive protein with clinical, endoscopic, and radiological activity in inflammatory bowel disease
-
Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, and radiological activity in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 707-712
-
(2005)
Inflamm Bowel Dis
, vol.11
, pp. 707-712
-
-
Solem, C.A.1
Loftus, E.V.2
Tremaine, W.J.3
-
16
-
-
0036161216
-
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
-
Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
-
(2002)
Gastroenterology
, vol.122
, pp. 512-530
-
-
Sandborn, W.J.1
Feagan, B.G.2
Hanauer, S.B.3
-
17
-
-
11144354315
-
Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
-
Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1051-1065
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
-
18
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
Breedveld, F.C.2
Kalden, J.R.3
-
19
-
-
27444448124
-
Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis
-
Sany J., Kaiser M.J., Jorgensen C., et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 1647-1649
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1647-1649
-
-
Sany, J.1
Kaiser, M.J.2
Jorgensen, C.3
-
20
-
-
24144491310
-
Variability factors in the clinical response to recombinant antibodies and IgG Fc- containing fusion proteins
-
Waiter H. Variability factors in the clinical response to recombinant antibodies and IgG Fc- containing fusion proteins. Expert Opin Biol Ther 5 Suppl 1 (2005) S29-S36
-
(2005)
Expert Opin Biol Ther
, vol.5
, Issue.SUPPL. 1
-
-
Waiter, H.1
|